小分子CGRP拮抗剂治疗前庭性偏头痛的早期经验
回顾性病例系列纳入17例接受gepants治疗的前庭性偏头痛成人患者,多数使用rimegepant,76.5%患者最困扰症状获缓解,84.6%认为帮助很大,未见严重不良事件。
要点
- Gepants耐受良好,未见严重不良事件。
- 76.5%患者最困扰症状获缓解,84.6%认为帮助很大。
- Rimegepant为最常用gepant(88.2%)。
核心结论
- Gepants耐受良好,是治疗前庭性偏头痛有前景的药物。
研究设计与样本
- 回顾性病例系列,三级学术中心,纳入17例接受gepants治疗的成人前庭性偏头痛患者。
主要发现
- 中位年龄54.1岁(SD 9.3),女性占70.6%,47.1%患者最困扰症状为眩晕。
- 最常用gepant为rimegepant(88.2%),其次ubrogepant(58.8%)、atogepant(23.5%)、zavegepant(5.9%)。
- 41.2%患者以终止发作方式用药,17.6%以预防方式用药,41.2%两种方式均尝试。
- 76.5%患者最困扰症状获缓解,84.6%认为药物对管理前庭性偏头痛症状帮助很大。
- 未见严重不良事件。
临床怎么用
- Gepants可作为前庭性偏头痛的治疗选择,耐受性良好。
局限性
- 回顾性病例系列,样本量小(17例),无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Blocking the activity of calcitonin gene-related peptide (CGRP) has emerged as a possible method for the prevention of vestibular migraine (VM). We aimed to investigate the effectiveness of small molecule CGRP antagonists (gepants) for the treatment of VM. STUDY DESIGN: Retrospective case series. SETTING: Tertiary academic center. METHODS: Adult patients diagnosed with VM who were treated with gepants were included. The gepants used included ubrogepant, rimegepant, atogepant, and zavegepant. A set of questionnaires was sent to patients including the Vestibular Migraine Patient Assessment Tool and Handicap Inventory (VM-PATHI), Dizziness Handicap Inventory (DHI), a survey regarding the details of their VM, and a survey focused on their experience with gepants. RESULTS: A total of 17 patients with VM who used gepants were included. Median age was 54.1 (SD 9.3) and the majority were female (70.6%). Vertigo was the most bothersome symptoms for 47.1% of patients. The most common gepant used was rimegepant (88.2%) followed by ubrogepant (58.8%), atogepant (23.5%), and zavegepant (5.9%). Seven patients (41.2%) took gepants in an abortive fashion, 3 patients (17.6%) used them as a preventative medication and 7 patients (41.2%) tried them as both a preventative or abortive medication. The majority of patients (76.5%) experienced relief of their most bothersome symptom after taking a gepant and 84.6% of this cohort claimed these medications helped quite a lot to manage their symptoms of VM. No serious adverse events were observed. CONCLUSIONS: Gepants are well-tolerated by patients and are promising agents for the treatment of vestibular migraine.
引用
- Patel EJ, Koziol K, Sharon JD, et al. Early Experience Treating Vestibular Migraine With Small Molecule CGRP Antagonists. Otolaryngol Head Neck Surg. 2026. PMID: 41774573. doi:10.1002/ohn.70196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。